Key facts
- Accuredit Therapeutics’s last known valuation is $147.0M (Aug 2025).
- It has raised $75.0M; the latest was Early Stage VC ($75.0M) in Aug 2025.
- Notable investors include Legend Capital, Cormorant Asset Management, Guangxi Kangzhe Guangming Pharmaceutical, Tibet Rhodiola Pharmaceutical Holding.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Accuredit Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Accuredit Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Accuredit Therapeutics
Developer of new drugs intended to treat severe diseases. The company develops new drugs and therapeutics based on gene editing, RNA editing and delivery technology, committing to treating life-threatening congenital genetic diseases and acquired diseases with safe and effective targeted drugs.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Ownership
- Privately Held (backing)
Accuredit Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Accuredit Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Accuredit Therapeutics in its N-PORT filings yet. We sweep new filings monthly.